Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market - Regional Analysis
Among region, North America is estimated to hold a dominant position in the global cancer chemotherapy associated nausea and vomiting therapeutics market over the forecast period. North America holds 44.6% of the market share, due to increasing adoption of inorganic strategies such as distribution and supply agreements by key players in North America region. For instance, in May 2022, Knight Therapeutics Inc., a Canada-based specialty pharmaceutical company, through one of its wholly-owned subsidiaries, and Helsinn Healthcare SA, a global biopharma company, announced that they had entered into an exclusive license, distribution, and supply agreement for AKYNZEO oral/IV (netupitant/palonosetron/ fosnetupitant/palonosetron) in Canada, Brazil, Argentina, Uruguay, and Paraguay, and ALOXI oral/IV (palonosetron) in Canada. AKYNZEO is 5-HT3 and NK1 receptor antagonist fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. ALOXI solution for injection is marketed in Canada for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy and highly emetogenic cancer chemotherapy, including high-dose cisplatin in adults. Under the terms of the agreement, Knight Therapeutics Inc. will have the exclusive right to distribute, promote, market, and sell the products in the licensed territories.
Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients